æªã æšé²æŽŸã«çãŸãè ãžã®èŠåãšããŠ
ãïŒ2æ7æ¥16æã«æ¹é¡ãããã³äžéšæ¹å€ïŒ
ãç§ãå»åž«ãšããŠçããŠããäžã§åŠäŒãããéèŠãªåœç¶±ãããè³ç¥çµå
ç§ããšããéèªã ã
ããã®2023å¹ŽïŒæå·ãæ¬æ¥æå
ã«å±ããã
ãïŒðïŒæïŒæ¥çŸåšãææ°åã¯ïŒæå·ã®ãŸãŸã«ãªã£ãŠãããã»ã»ã»ïŒ
ãä»åããã¯ã¯ãã³æ¥çš®ãšç¥çµé害ããšããç¹éãçµãŸããŠãããã€ã³ãã«ã¯ã¯ãã³ãæ¥æ¬è³çã¯ã¯ãã³ãHPVã¯ã¯ãã³ãšããããã€ãã®ã¡ã³ããŒãã«å ããŠãSARS-CoV-2ã¯ã¯ãã³ã«ã€ããŠã®ç·èª¬ãæ²èŒãããŠããã
ãã¿ã€ãã«ã¯ãCOVID-ïŒïŒã¯ã¯ãã³æ¥çš®åŸã«çããGuillain-Barreçå矀ãå
ç«æ§è¡æ æ§è¡å°æ¿æžå°çããèè
ã¯è²¡åç蚺çæã®é»å²©çŸ©ä¹å
çãšãåžäº¬å€§åŠä»å±æºå£ç
é¢ã®å¹³äºå©æå
çã ããäºäººãšããHPVã¯ã¯ãã³æ¥çš®é¢é£ç¥çµå
ç«ç°åžžçå矀ïŒHANSïŒã«ã€ããŠåºŠã
åèªã§ç·èª¬ãæžãããŠãããããããèŠåºäžéšçå矀ããšäœçœ®ä»ããŠãããããç§ããã€ãŠãèŠåºäžéšã«ç
å€ãæããå
ç«ä»åšæ§äžæ¢ç¥çµé害ã®ã±ãŒã¹ãæ
åœããããšããããHANSãšå®çŸ©ãããŠããç
æ
ãšéåžžã«äŒŒãçç¶ãåããŠããããšãçµéšããŠãããã ããç§çã«ã¯ãã®èª¬æã¯ããããè
ã«èœã¡ãã
ã
ã話ãéžãããä»åã®ã¯ã¯ãã³çŠãããäºäººãã©ã®ããã«èããŠããã®ãã¯ãåžžã
æ°ã«ãªã£ãŠãããã§æ©éèªãã§ã¿ããå
å®¹ã¯æ³å以äžã ã£ãããã¡ããSARS-CoV-2ã¯ã¯ãã³æ
éæŽŸã®äººéãªãæ¢ç¥ã®å
容ã§ã¯ããã®ã ãããããããããåã®ç¥ããå»åŠéèªã«æ²èŒã§ããç¶æ³ã«ãªã£ããšæããšãéäžã®æãããã
ã
ãå
容ã«è§ŠããŠãããšãåœã¯ã¯ãã³ãåå ãšèããããGuillain-Barreçå矀ãšã¯ã¯ãã³èªçºæ§å
ç«æ§è¡å°æ¿æžå°çïŒä»¥äžãVITTïŒã«é¢ããäž»ã«æµ·å€è«æã«ã€ããŠæ€èšãããŠããããããŠããåå ãšãããç«å Žãšãåå ã§ã¯ãªãããšããç«å Žã®äž¡æ¹ããã¡ããšç޹ä»ããŠãããç§åŠçãªå
¬å¹³ããä¿ãããŠãããVITTçºçããã¡ã«ããºã ã®å³ãéåžžã«ããããããã
ã
ããããŠãæ¬ã¯ã¯ãã³ã®åé¡ç¹ããšããç« ãæ»ããŸãã£ãŠãããå®ã¯ãããæ¬é¡ã ããšèšããã°ããã ãæåã«éçåäºé²ãå«ããæå¹æ§ã®æ ¹æ ãäžæãªããšãèšããããã«ã
ãçŽ°èæ§å
ç«ã®äœäžãåŒãèµ·ããããšã
ãæäœäŸåæ§å
ç«å¢åŒ·ã«ã€ããŠã®æžå¿µã
ãã¹ãã€ã¯èçœã«ç¥çµæ¯æ§ãããããšã
ãæ¥çš®ã«ããã¹ãã€ã¯èçœãæç¶çã«åæãä¿é²ãããŠããããšã
ãâ
åã€ã³ã¿ãŒãã§ãã³å¿çã®æå¶ã«ããèªç¶å
ç«ã®é害ãããããããããææçãæªæ§è
«çã«å¯Ÿãããªã¹ã¯ãé«ããŠããããšã
ããããŠå¥ã®æ©åºïŒã°ã¢ãã³ïŒééã®å¢å ïŒã§ãè
«ççºçãªã¹ã¯ãé«ããŠããããšã
ãããã«ã¯mRNAã®é転åã瀺åãããŠããããšãŸã§ã
æ ¹æ è«æãæç€ºããªããè§ŠããããŠãããããã¯ãªãã¡ã¬ã³ã¹éãšããŠãããªãæçšã ãæé£ãã
ãåœã¯ã¯ãã³ã«ããèªç¶å
ç«é害ã«é¢ããã«ã¹ã±ãŒããæ¥æ¬èªã§å³ã«ç€ºããŠé ããŠãããåãããããã
ãçµèªã«ãããããã¯HPVã¯ã¯ãã³æ¥çš®åŸå¯åå¿ãé·æã«èгå¯ããããšã§ãéç床ã®ããŒã¯ã¯ååæ¥çš®ããïŒå¹Žã§ããããšãå ±åãããããšããæç« ãæ·»ããããŠããã®ãéåžžã«å°è±¡æ·±ãã
ãè³ç¥çµå ç§å»ãããç é¢ãªãããã®éèªãå®æè³ŒèªããŠããå Žåãå€ãããã®ãã¡æžæ¶ã«äžŠã¶ã ãããããåç§ã®å»åž«ã¯ãã¡ãããä»ç§ãä»è·çš®ã®å»çåŸäºè ã«ãäžèªãå§ãããåãããåã¯ã¯ããšããããã§ãã人éãèšã£ãŠãããšã¯å®ã¯å šãŠæ ¹æ ãããããšããããšãæãç¥ããæ¥ãå ¥ããããïŒïŒïŒ
è£ïŒä»¥äžã¯åå¿ã¡ã¢
ãå人çã«ã¯ã¹ãã€ã¯èçœã奜äžç掻æ§åãšå¥œäžç现èå€ãã©ããïŒNETsïŒïŒâçœè¡çã®äžã€ã§ãã奜äžçããç¶²ã®ãããªæ§é ç©ã§çްèãæç²ã殺èããããšããæãç¶²ã®ãããªæïŒåœ¢æã®ä¿é²ã«é¢ãã£ãŠããããšãã話ãè峿·±ãã£ãã
ãNETsã¯éçææçã§ã貪é£ã§ã¯è¿œãã€ããªãã»ã©çްèãå€ãå Žåã«ãæè¿ãäžç¶²æå°œã«ããããã®éèŠãªåœ¹å²ãæ
ã£ãŠããããããããããè¡å°æ¿éç©ããã£ããªã³åœ¢æãä¿é²ããŠããŸãããã®ããDICã®åå ãšãªããšãããæããè¡æ 圢æèªäœã¯ãæªãéšåã®è¡æµã鮿ããŠææãå°ã蟌ããããšããæŠç¥ãªã®ã§ããããªãã«æçŸ©ã¯ããã®ã ãã€ãŸããææã§ããªãã®ã«ãNETs圢æãä¿é²ããããããã ãã æå³ããªãè¡æ 圢æåŸåã ããé«ãŸãããšããããšã«ãªãã
ããŸããANCAïŒæå¥œäžç现è質æäœïŒé¢é£è¡ç®¡çã¯ãææãªã©ã奿©ã«ANCAã®å¯Ÿå¿æåïŒMPOãPR3ïŒãè¡ç®¡äžç®ã«è¡šåºãããããã«è§Šãã奜äžçãæŽ»æ§åãNETsæŸåºãä¿é²ãããããšã§èµ·ãããã€ãŸããNETs圢æã®ä¿é²ã«ããè¡ç®¡çãæ¹èµ·ããè¡ç®¡å
ç®å£æ»ã®åå ãšãªãã
ãã¹ãã€ã¯èçœãè¡ç®¡é害ã®åå ãšãªãã¡ã«ããºã ã¯è¡å°æ¿æŽ»æ§åã ãã§ã¯ãªãã®ã ããªãã ããã¯ãããŸãã«ãè¡ç®¡ã«å¯Ÿããæ¯æ§ã匷ãããã§ã¯ãªããã
ãäžèšã®ç¥çµæ¯æ§ãå«ãããããããªæ¯æ§ã®åŒ·ããã®å©çšããããšæã£ããã®ã ãããŸãã«ãã»ã³ã¹ãæªãããããããé°è¬è«ãåºãŠãããããšããèšãããããªãã